Loading clinical trials...
Loading clinical trials...
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Eye Center South
Dothan, Alabama, United States
Arizona Eye Center
Chandler, Arizona, United States
Walman Eye Center
Chandler, Arizona, United States
Shasta Eye Medical Group, Inc.
Redding, California, United States
Wolstan & Goldberg Eye Associates
Torrance, California, United States
Eye Associates of Colorado Springs
Colorado Springs, Colorado, United States
West Coast Eye Institute
Lecanto, Florida, United States
Emory University Eye Center
Atlanta, Georgia, United States
Coastal Research Associates, LLC
Roswell, Georgia, United States
The Eye Care Institute
Louisville, Kentucky, United States
Start Date
February 24, 2016
Primary Completion Date
January 26, 2021
Completion Date
January 26, 2021
Last Updated
February 23, 2022
144
ACTUAL participants
Bimatoprost SR
DRUG
Sham Bimatoprost SR
DRUG
Selective Laser Trabeculoplasty
PROCEDURE
Sham Selective Laser Trabeculoplasty
PROCEDURE
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441